Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 10 · below the Ichimoku cloud · RSI 39 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $552.6K | 0.00% | 425.11K | +33% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LUNG trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Rose Geoffrey BeranOfficer | Sale at price 2.26 per share. | 7.9K | $17.81K |
| Aug 31, 2026 | Radhakrishnan SrikanthChief Technology Officer | Sale at price 2.26 per share. | 14.2K | $32.19K |
| Aug 31, 2026 | French Glendon E IiiChief Executive Officer | Sale at price 2.26 per share. | 41.9K | $94.65K |
| Aug 31, 2026 | Lehman David AaronGeneral Counsel | Sale at price 2.26 per share. | 14.3K | $32.40K |
| Jun 4, 2026 | Ferrari Richard MDirector | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Jun 4, 2026 | Mead Dana G JrDirector | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Jun 4, 2026 | Florin Daniel PDirector | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Jun 4, 2026 | Burns Thomas WilliamDirector | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Jun 4, 2026 | Melenikiotou GeorgiaDirector | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Jun 4, 2026 | Sullivan TiffanyDirector | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Jun 1, 2026 | French Glendon E IiiChief Executive Officer | Sale at price 1.54 - 1.57 per share. | 56.1K | $86.88K |
| May 31, 2026 | Rose Geoffrey BeranOfficer | Sale at price 1.54 per share. | 8K | $12.36K |
| May 31, 2026 | Radhakrishnan SrikanthChief Technology Officer | Sale at price 1.54 per share. | 14.5K | $22.32K |
| May 31, 2026 | Lehman David AaronGeneral Counsel | Sale at price 1.54 per share. | 14.6K | $22.48K |
| Mar 1, 2026 | Lehman David AaronGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 150K | — |
| Mar 1, 2026 | Rose Geoffrey BeranOfficer | Stock Award(Grant) at price 0.00 per share. | 100K | — |
| Mar 1, 2026 | Radhakrishnan SrikanthChief Technology Officer | Stock Award(Grant) at price 0.00 per share. | 175K | — |
| Mar 1, 2026 | Rose Geoffrey BeranOfficer | Sale at price 1.43 per share. | 7.7K | $11.06K |
| Mar 1, 2026 | Radhakrishnan SrikanthChief Technology Officer | Sale at price 1.43 per share. | 10.5K | $14.99K |
| Mar 1, 2026 | French Glendon E IiiChief Executive Officer | Sale at price 1.43 per share. | 67.8K | $96.97K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.8 | -3.7 | -18.4 | -0.8 | 28.9 | -21.2 | 25.4 | 46.0 | -19.7 | -7.9 | −20.4% | ||
| 2025 | -16.3 | 51.8 | -21.9 | -28.2 | -29.6 | -23.8 | -29.0 | -7.1 | -5.3 | 23.5 | -19.0 | 36.4 | −67.5% |
| 2024 | 4.2 | -30.6 | 0.5 | -17.9 | -4.7 | -12.6 | 9.0 | 5.9 | 13.3 | -24.6 | 3.2 | 5.3 | −46.7% |
| 2023 | 5.5 | 26.3 | -0.4 | 5.1 | 2.2 | 9.2 | 6.8 | -25.3 | -1.2 | -14.9 | 24.0 | 17.0 | +51.2% |
| 2022 | -24.1 | 7.8 | -5.5 | -2.9 | -24.2 | -19.4 | 15.8 | 7.8 | -9.3 | -19.8 | -54.9 | 40.0 | −73.7% |
| 2021 | -17.8 | 0.2 | -19.5 | 2.8 | -8.7 | 2.8 | -10.1 | 1.3 | -10.5 | 8.2 | -17.0 | -0.7 | −53.5% |
| 2020 | 28.9 | 27.3 | +64.1% |
Buy / hold / sell counts
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.